Are there any related-party transactions or family relationships disclosed for Envoy Medical’s new finance executive?

Envoy Medical states that Robert Potashnick has not been involved in any transactions requiring disclosure under Item 404(a) of Regulation S-K and has no family relationship with any board member or executive officer.

Envoy Medical appoints Potashnick chief accounting officer

Q: What executive change did Envoy Medical, Inc. (COCH) announce on August 24, 2026?

Envoy Medical, Inc. appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance on August 24, 2026. He will also continue to serve as the company’s principal financial officer and principal accounting officer, formalizing his prior contractor role as Interim Chief Financial Officer.

Q: Does Envoy Medical’s agreement with Robert Potashnick include severance benefits?

Yes. The Employment Agreement provides for six months of severance compensation in connection with certain terminations of Robert Potashnick’s employment with Envoy Medical, Inc. (COCH).

Envoy Medical, Inc. (COCH) appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Envoy Medical, Inc. (COCH) appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026. He will continue to serve as the company’s principal financial officer and principal accounting officer, transitioning from his prior contractor role as Interim Chief Financial Officer.

Under an Employment Agreement dated August 24, 2026, Mr. Potashnick will receive a base salary of $315,000 per year, an initial target annual bonus equal to 15% of base salary based on performance goals, and an initial equity award of 250,000 stock options with an exercise price of $0.746 per share, matching the Class A common stock closing price on his hire date. The agreement includes six months of severance compensation in certain termination scenarios. The company states he has no related-party transactions requiring disclosure and no family relationships with directors or executive officers.

Insights

Analyzing...

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Base salary: $315,000 per year Target bonus percentage: 15% of base salary Initial stock options: 250,000 stock options +3 more

6 metrics

Base salary $315,000 per year Compensation for Chief Accounting Officer and Vice President of Finance under Employment Agreement dated August 24, 2026

Target bonus percentage 15% of base salary Initial target bonus payable upon achievement of performance goals

Initial stock options 250,000 stock options Equity award to Robert Potashnick as part of his compensation package

Stock option exercise price $0.746 per share Exercise price equals closing price of Class A Common Stock on August 24, 2026

Severance compensation period Six months Severance compensation in connection with certain terminations of employment

Age of executive 46 Age of Robert Potashnick at the time of appointment

Key Terms

principal financial officer, principal accounting officer, stock options, exercise price, +2 more

6 terms

principal financial officer financial

"will continue the duties as the Company’s principal financial officer"

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

principal accounting officer financial

"and principal accounting officer"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

stock options financial

"an initial equity award of 250,000 stock options at an exercise price"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"stock options at an exercise price of $0.746 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

severance compensation financial

"provides for six months of severance compensation in connection"

Emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Envoy Medical, Inc. (COCH) announce on August 24, 2026?

Envoy Medical, Inc. appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance on August 24, 2026. He will also continue to serve as the company’s principal financial officer and principal accounting officer, formalizing his prior contractor role as Interim Chief Financial Officer.

What is the annual base salary for Envoy Medical’s new Chief Accounting Officer?

Under his Employment Agreement, Robert Potashnick will receive a base salary of $315,000 per year. This is part of his compensation package as Chief Accounting Officer and Vice President of Finance at Envoy Medical, Inc. (COCH).

What bonus opportunity does Envoy Medical (COCH) provide to Robert Potashnick?

Envoy Medical’s Employment Agreement grants Robert Potashnick an initial target bonus equal to 15% of his base salary, payable upon the company’s achievement of specified performance goals. This bonus is in addition to his base salary and equity award.

What equity award did Envoy Medical grant to Robert Potashnick?

Envoy Medical granted Robert Potashnick an initial equity award of 250,000 stock options with an exercise price of $0.746 per share, which is the closing price of the company’s Class A Common Stock on his August 24, 2026 hire date.

Does Envoy Medical’s agreement with Robert Potashnick include severance benefits?

Yes. The Employment Agreement provides for six months of severance compensation in connection with certain terminations of Robert Potashnick’s employment with Envoy Medical, Inc. (COCH).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/27/2026 - 05:30 PM Accepted by SEC EDGAR 08/27/2026 - 05:29 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 24, 2026

ENVOY MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40133

86-1369123

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

4875 White Bear Parkway White Bear Lake, MN		55110
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 900-3277

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share	COCH	The Nasdaq Stock Market LLC
Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share	COCHW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On August 24, 2026, Envoy Medical, Inc. (the “Company”) appointed Robert Potashnick to serve as the Company’s Chief Accounting Officer and Vice President of Finance. Mr. Potashnick had previously served as Interim-Chief Financial Officer of the Company on a contractor basis. Mr. Potashnick will continue the duties as the Company’s principal financial officer and principal accounting officer.

Mr. Potashnick was hired to serve as Chief Accounting Officer and Vice President of Finance pursuant to the terms of an Employment Agreement dated August 24, 2026 (the “Employment Agreement”). Pursuant to the terms of the Employment Agreement, Mr. Potashnick is entitled to a base salary of $315,000 per year, an initial target bonus equal to 15% of his base salary payable upon the Company’s achievement of certain performance goals, and an initial equity award of 250,000 stock options at an exercise price of $0.746 per share, the closing price of the Company’s Class A Common Stock on the hire date. The Employment Agreement also provides for six months of severance compensation in connection with certain terminations of Mr. Potashnick’s employment.

Mr. Potashnick, 46, has provided consulting services through Oasis Business Consulting, LLC since October 2024, including to the Company beginning in June 2025. Previously, Mr. Potashnick served as the Chief Financial Officer of Flutterbee Education Group from January 2024 to October 2024 and FOXO Technologies, Inc. (NYSE American: FOXO) from January 2021 to September 2023. From 2017 to 2020, Mr. Potashnick served in capital planning and business development finance roles at UnitedHealth Group (NYSE American: UNH). Before that, from 2010 to 2017, Mr. Potashnick worked as a certified public accountant at PricewaterhouseCoopers LLP. Mr. Potashnick holds a Bachelor of Arts degree in Economics from Northwestern University, a Master’s Degree in Accountancy from the University of Illinois, and an MBA (Finance/Strategy) from DePaul University.

Mr. Potashnick (a) is not a party to any arrangement or understanding with any other person pursuant to which he was selected to serve as Interim Chief Financial Officer of the Company, (b) has not been involved in any transactions with the Company or related persons of the Company that would require disclosure under Item 404(a) of the Regulation S-K, and (c) does not have any family relationship with any members of the Board or any executive officer of the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1		Employment Agreement between Envoy Medical Corporation and Robert Potashnick, dated August 24, 2026.
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENVOY MEDICAL, INC.

August 27, 2026	By:	/s/ Robert Potashnick
		Robert Potashnick
		Chief Account Officer; VP – Finance

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Agreements & Contracts

EX-10.1 EMPLOYMENT AGREEMENT BETWEEN ENVOY MEDICAL CORPORATION AND ROBERT POTASHNICK, DA 90.8 KB